Department of Child Health, Teaching Hospital, Centre Hospitalier Universitaire Mère Enfant Tsaralàlana, Antananarivo, Madagascar.
Department of Child Health, Teaching Hospital, Centre Hospitalier Universitaire Mère Enfant Tsaralàlana, Antananarivo, Madagascar.
Vaccine. 2018 Nov 12;36(47):7198-7204. doi: 10.1016/j.vaccine.2017.08.091. Epub 2017 Sep 25.
Rotavirus vaccine was introduced into the Extended Program on Immunization in Madagascar in May 2014. We analyzed trends in prevalence of all cause diarrhea and rotavirus hospitalization in children <5years of age before and after vaccine introduction and assessed trend of circulating rotavirus genotypes at Centre Hospitalier Universitaire Mère Enfant Tsaralalàna (CHU MET).
From January 2010 to December 2016, we reviewed the admission logbook to observe the rate of hospitalization caused by gastroenteritis among 19619 children <5years of age admitted at the hospital. In June 2013-December 2016, active rotavirus surveillance was also conducted at CHUMET with support from WHO. Rotavirus antigen was detected by EIA from stool specimen of children who are eligible for rotavirus gastroenteritis surveillance at sentinel site laboratory and rotavirus positive specimens were further genotyped at Regional Reference Laboratory by RT-PCR.
Diarrhea hospitalizations decreased after rotavirus vaccine introduction. The median proportion of annual hospitalizations due to diarrhea was 26% (range: 31-22%) before vaccine introduction; the proportion was 25% the year of vaccine introduction, 17% in 2015 and 16% in 2016. Rotavirus positivity paralleled patterns observed in diarrhea. Before vaccine introduction, 56% of stool specimens tested positive for rotavirus; the percent positive was 13% in 2015, 12% in 2016. Diverse genotypes were detected in the pre-vaccine period; the most common were G3P[8] (n=53; 66%), G2P[4] (n=12; 15%), and G1P[8] (n=11; 14%). 6 distinct genotypes were found in 2015; the most common genotype was G2P[4] (n=10; 67%), the remaining, 5, G12[P8], G3[P8], G1G3[P4], G3G12[P4][P8] and G1G3[NT] had one positive specimen each.
Following rotavirus vaccine introduction all-cause diarrhea and rotavirus-specific hospitalizations declined dramatically. The most common genotypes detected in the pre-vaccine period were G3P[8] and G2P[4] in 2015, the post vaccine period.
2014 年 5 月,轮状病毒疫苗被纳入马达加斯加扩大免疫规划。我们分析了疫苗引入前后 5 岁以下儿童所有病因腹泻和轮状病毒住院的流行趋势,并评估了塔那那利佛圣母儿童医院(CHUMET)循环轮状病毒基因型的趋势。
2010 年 1 月至 2016 年 12 月,我们查阅了住院日志,观察了医院收治的 19619 名 5 岁以下儿童因肠胃炎住院的比例。2013 年 6 月至 2016 年 12 月,在世界卫生组织的支持下,还在 CHUMET 开展了主动轮状病毒监测。通过 EIA 从哨点实验室符合轮状病毒肠胃炎监测条件的儿童粪便标本中检测轮状病毒抗原,对轮状病毒阳性标本在区域参考实验室进一步用 RT-PCR 进行基因分型。
轮状病毒疫苗引入后,腹泻住院人数减少。疫苗引入前,每年因腹泻住院的中位数比例为 26%(范围:31%-22%);疫苗引入当年的比例为 25%,2015 年为 17%,2016 年为 16%。轮状病毒阳性与腹泻观察到的模式一致。疫苗引入前,56%的粪便标本检测出轮状病毒阳性;2015 年阳性率为 13%,2016 年为 12%。在疫苗引入前的时期检测到多种基因型;最常见的是 G3P[8](n=53;66%)、G2P[4](n=12;15%)和 G1P[8](n=11;14%)。2015 年发现 6 种不同的基因型;最常见的基因型是 G2P[4](n=10;67%),其余 5 种基因型分别是 G12[P8]、G3[P8]、G1G3[P4]、G3G12[P4]和 G1G3[NT],每种基因型均有 1 个阳性标本。
轮状病毒疫苗引入后,所有病因腹泻和轮状病毒特异性住院率显著下降。疫苗引入前最常见的基因型是 G3P[8]和 G2P[4],2015 年疫苗引入后则是 G2P[4]。